Roman Jirak

Roman Jirak

Auto-generated profile, based on publicly available information

Roman Jirak

Department of Psychiatry, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Clinical Biochemistry
Verified
Journal Article
Closed access
JKJana Kodydková
Jana Kodydková
LVLucie Vávrová
Lucie Vávrová
MZMiroslav Zeman
Miroslav Zeman
RJRoman Jirák
Roman Jirák
JMJaroslav Macášek
Jaroslav Macášek
AŽAleš Žák
Aleš Žák

1 April 2014 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JPJan Pláteník
Jan Pláteník
ZFZdeněk Fišar
Zdeněk Fišar
RBRichard Buchal
Richard Buchal
RJRoman Jirák
Roman Jirák
EKEva Kitzlerová
Eva Kitzlerová
JRJiří Raboch
Jiří Raboch

2 June 2016 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
ZFZdeněk Fišar
Zdeněk Fišar
JHJana Hroudová
Jana Hroudová
JHJana Hroudová
Jana Hroudová
HHHana Hansíková
Hana Hansíková
JSJana Spá
Jana Spá
OVOvá
Ová
Mitochondrial dysfunctions significantly contribute to the pathogenesis of Alzheimer’s disease (AD). Here, we studied the relationship between AD and changes in the mitochondrial rates of respiration in blood platelets, respiratory chain complexes activity, and coenzyme Q10 plasma concentrations. In intact platelets obtained from AD patients, we observed a decrease in endogenous basal respiration rates, a decrease in the maximal capacity of the electron transport system (ETS), and higher respiratory rates after inhibiting complex I of the ETS. When normalized for citrate synthase activity, rotenone inhibited respiratory rates and complex I activity was significantly altered. In permeabilized platelets, mitochondrial respiration was completely rescued by the addition of complex I substrates. The changes in mitochondrial respiratory parameters were not associated with the progression of AD except for the capacity of the ETS in permeabilized platelets. In AD, complex I activity was increased, complex IV activity was decreased, and coenzyme Q10 plasma concentrations were decreased. Our data indicate that both insufficiency in substrates entering into the oxidative phosphorylation system and functional disturbances in the ETS complex are responsible for the decrease in respiration observed in intact platelets in AD patients. Analyses of complex IV activity, the respiratory rates of intact platelets, and the capacity of the ETS in permeabilized platelets may enable the characterization of mitochondrial dysfunctions in the initial stage of AD.

1 January 2013 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
JRJiří Raboch
Jiří Raboch
MZMartina Zvěřová
Martina Zvěřová
ZFZdeněk Fišar
Zdeněk Fišar
RJRoman Jirák
Roman Jirák
EKEva Kitzlerová
Eva Kitzlerová
JHJana Hroudová
Jana Hroudová
Background:Cortisol is presumed to be a risk factor for stress- and age-related disorders, such as depressive disorder and Alzheimer’s disease (AD). The aim of this study was to investigate the association of plasma cortisol concentration with AD i...

1 January 2010 in Folia Biologica
Verified
Journal Article
Open access
PDF file
MZMiroslav Zeman
Miroslav Zeman
MJM. Jáchymová
M. Jáchymová
RJR. Jirák
R. Jirák
MVMarek Vecka
Marek Vecka
ETE. Tvrzická
E. Tvrzická
AŽA. Žák
A. Žák
The prevalence of metabolic syndrome as well as the occurrence of depressive disorder, which are both connected with increased risk of diabetes mellitus type 2 and cardiovascular diseases, is continually increasing worldwide. These disorders are interconnected at various levels; the genetic one seems to be promising. Contribution of genetic factors to the aetiopathogenesis of depressive disorder weighs within the range 40–50 %, whereas the genetic background for the manifestation of metabolic syndrome is more complicated. In this pilot study, we investigated the incidence of polymorphisms in several genes supposed to play a role in the development of both depressive disorder and metabolic syndrome such as brain-derived neurotrophic factor, methylenetetrahydrofolate reductase, tyrosine hydroxylase, and endothelial nitric oxide synthase. The entire group consisted of 42 patients with depressive disorder, 57 probands with metabolic syndrome and 41 control individuals. We found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).

10 January 2004 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
MBMarie Bičíková
Marie Bičíková
DŘDaniela Řípová
Daniela Řípová
Martin HillMartin Hill
Martin Hill
RJRoman Jirák
Roman Jirák
HHHelena Havlíková
Helena Havlíková
RHRichard Hampl
Richard Hampl
The early differential diagnosis of Alzheimer's disease (AD) remains still problematic. We developed a laboratory test enabling us to distinguish patients with AD from those with vascular dementia (VD) and healthy subjects. The AD group consisted of 22 women and 18 men. The VD group consisted of 16 women and 8 men. Age-matched controls consisted of 12 women and 9 men. Plasma pregnenolone sulfate (PregS), dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) were determined by radioimmunoassay. 17-Hydroxypregnenolone (17Preg) and 7-hydroxylated metabolites of DHEA (7alphaDHEA, 7betaDHEA) were determined by radioimmunoassay after separation by high performance liquid chromatography (HPLC). Homocysteine (Hcy), cysteine (Cys), cysteinylglycine (Cysgly) and glutathione (GSH) were measured by HPLC. The ANOVA results of significant between-group differences were as follows: The PregS and the 17-Preg and DHEAS levels were independent from the diagnosis. The 7alphaDHEA levels significantly depended on the sex (p < 0.05) and diagnosis (p < 0.01). Amino-thiols were influenced by the diagnosis (p < 0.01, p = 0.0541, p < 0.01 and p = 0.0536 for Cys, Hcy, Cysgly and GSH, respectively). Using a stepwise backward regression analysis, the following parameters were obtained: X = 11.5 + 4.03 x sex +1.09 x Hcy + 0.190 x PregS - 4.76 x DHEAS + 3.00 x DHEA - 34.3 x 77alphaDHEA - 0.885 x Cysgly from which P-value as a discriminator was calculated according to the formula: P = 1/(1 + e(-x)). Then, for P > 0.5, a subject was considered as AD-positive (with 89% correct prediction). The opportunity of early differential diagnosis of AD should help physicians to use suitable treatment for retardation of pathological processes.